Key Highlights
- ARYC trades around $0.000001, with a market Capitalization of only a few thousand dollars.
- The company's last audited Annual Report on file covers fiscal 2014, and filing activity effectively ceased around 2019.
- Arrayit's former president was charged in 2020 in a securities- and health-care-fraud case that later proceeded to conviction.
- Over one billion shares are outstanding, implying heavy historical dilution.
A stock quoted at a hundredth of a penny rarely rewards a search for the "next catalyst," and Arrayit Corporation (OTC:ARYC) is a textbook example. The microarray-diagnostics company once pitched itself as a life-sciences innovator, but it stopped filing audited financial reports years ago, its shares trade at essentially zero, and its former Leadership became the subject of a high-profile federal Fraud prosecution. For anyone examining ARYC today, the story is about status, not momentum.
Company and Latest Development
Arrayit describes itself as a developer of microarray tools and components for analyzing genetic variation, offering custom printing and analysis of microarrays for research and diagnostics. The Nevada-incorporated, Sunnyvale, California-based company was formerly known as Integrated Media Holdings and is led by chief executive Rene Schena. The most consequential development is what is missing: according to SEC EDGAR, Arrayit's last annual report on Form 10-K covered fiscal 2014, and its filing activity effectively ceased around 2019. That leaves it a delinquent, non-reporting issuer whose shares trade over the counter at sub-penny levels.
What Is Driving Attention Around ARYC?
There is no verifiable forthcoming corporate catalyst to point to. Interest in a name like ARYC is typically speculative penny-stock activity rather than a response to company news, and no fresh operational development is identifiable from public sources. The company's profile is also shaped by legal history: as a matter of public record, U.S. authorities charged Arrayit's president in 2020 in a securities- and health-care-fraud case tied to Marketing claims around COVID-19 and allergy testing, a matter that later proceeded to conviction. That backdrop, not a growth catalyst, defines the ticker.
Key Numbers and Company Position
Market data show ARYC quoted around $0.000001 with a market capitalization of only a few thousand dollars and well over one billion shares outstanding. Its most recent audited annual report on file covers fiscal 2014. Because the company is no longer a current SEC filer, up-to-date, reliable financial figures are not available, and any Revenue or loss data circulating on aggregators should be treated as stale. The absence of current financial disclosure is itself the defining number here.
What Could Come Next?
Realistically, the near-term path does not include conventional catalysts. Returning to good standing would require years of delinquent filings to be brought current and audited, a demanding and uncertain process that few dormant issuers complete. Absent that, ARYC is likely to remain a dormant, sub-penny quote, potentially subject to expert-market restrictions that can limit whether ordinary investors can even obtain quotes or trade. Micro-cap microarray and diagnostics developers also face a crowded, capital-intensive market dominated by far larger, well-funded competitors, leaving little obvious route back to relevance for a company in Arrayit's position.
Risks to Watch
The risks are severe and largely binary. With no current financial reporting, investors are effectively flying blind on assets, liabilities, cash, and whether the Business operates at all. Sub-penny expert-market securities carry extreme illiquidity, wide spreads, and a high risk of total loss, and quotes can be difficult to obtain or act on. The company's litigation legacy compounds reputational and legal uncertainty, and the enormous share count, well into the billions, implies heavy historical dilution that would weigh on any future Equity value. There is no verified operating pipeline to underpin the shares.
A Delinquent Shell, Not a Pending Milestone
Arrayit Corporation is best understood not as a stock awaiting a catalyst but as a delinquent, non-reporting shell trading at a fraction of a cent, shadowed by a documented federal fraud case against its former leadership. Rather than a pending milestone, the development worth monitoring would be any resumption of audited financial filings, which currently appears unlikely.


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...